Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Athena Neurosciences

Executive Summary

Athena Neurosciences: Will submit data on a recently completed study of Zanaflex (tizanidine) showing that treated multiple sclerosis patients had "statistically significant reductions in spasticity compared to the placebo group," firm says following meeting with FDA on "not approvable" letter for the alpha-2 agonist. Athena plans to amend its NDA "before the end of September." Athena received the "not approvable" letter in March...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026597

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel